OPKO Health Agrees to Buy Cytochroma
Posted on January 08, 2013 at 17:29 PM EST
OPKO Health, Inc. (NYSE: OPK ) has entered into a definitive agreement to acquire Cytochroma Inc. (Markham, Canada) whose lead products, both in phase 3 clinical trials, are Replidea™ (coded CTAP101 Capsules), a vitamin D prohormone to treat secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD) and